The average market capitalisation cut-off for a stock to make it to the largecap category in the upcoming Amfi semi-annual categorisation is expected to be Rs 84,000 crore compared to an average of Rs 67,000 crore in the six months ending December 2023, Nuvama said in a note. Meanwhile, the midcap threshold is likely to … Read more
“In North America, Revlimid is the key contributor and again, speciality drugs for Zydus Lifesciences that will keep on increasing EBITDA margins towards 29-30% and also in the valuation-wise Zydus Life is not trading at much higher valuations like Sun, therefore we feel that Zydus Life is also a second stock which can see good … Read more
Recent trading sessions have experienced significant volatility in the Indian markets, driven by concerns related to the budget and geopolitical developments in the Red Sea region. However, these corrections also offer a great opportunity for investors to enter good-quality stocks.In light of the prevailing conditions, three stocks have formed a strong setup on the technical … Read more
